View Cart (0 items)

Pharmaceutical

GSK to start clinical trials on new Ebola vaccine

No Comments
London-listed pharmaceuticals company GlaxoKlineSmith will start clinical safety trials for its experimental Ebola vaccine in the U.S. as early as next week.
Read More

Roche acquires InterMune for $8.3 billion in move to strengthen respiratory portfolio

No Comments
Swiss pharmaceuticals group Roche revealed this week that it has agreed to acquire California-based biotechnology company InterMune Inc. in a deal worth $8.3 billion.
Read More

Tighter restrictions to be placed on hydrocodone combination products

No Comments
Medicines containing hydrocodone, a highly addictive painkiller, will be subject to more restrictions under new rules published by the U.S. Drug Enforcement Administration (DEA) this week.
Read More

FDA warns consumers to avoid fraudulent Ebola treatment products

No Comments
The agency said that it had seen and received consumer complaints about various products being offered online that are claimed to either prevent the Ebola virus or treat the infection.
Read More

Sanofi, MannKind agree on $925 million deal for inhaled insulin therapy

No Comments
Under the exclusive agreement with MannKind Corporation the two companies will collaborate on development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.
Read More

Alvogen acquires South Korea's Dream Pharma

No Comments
Pharmaceutical company Alvogen has agreed to purchase Dream Pharma, based in South Korea, for $187 million in cash.
Read More

US pharmaceutical packaging products market valued at $22.1 billion

No Comments
U.S. demand for pharmaceutical packaging products is expected to increase slightly in the next few years as drug makers upgrade the barrier, security and functional properties of their packaging systems.
Read More

FDA reveals details on generic drugs watchdog reorganization

No Comments
The U.S. Food and Drug Administration (FDA) has announced details of its long-awaited reorganization of the Office of Generic Drugs (OGD).
Read More

Mylan Buys Abbott's Non-U.S. Generic Drugs Portfolio

No Comments
The deal will cost an estimated $5.3 billion and involve more than 100 products in several key areas.
Read More

Salix Pharmaceuticals to merge with Cosmo subsidiary

No Comments
U.S.-based Salix Pharmaceuticals Ltd. has announced plans to merge with a unit of Italian company Cosmo Pharmaceuticals, Cosmo Technologies Ltd.
Read More